A5063518444- Monoclonal and Polyclonal Antibodies Research
- Nanofabrication and Lithography Techniques
- HER2/EGFR in Cancer Research
- Molecular Junctions and Nanostructures
- Innovative Microfluidic and Catalytic Techniques Innovation
- Hormonal Regulation and Hypertension
- Advanced Biosensing Techniques and Applications
- Cellular transport and secretion
- Nanoparticle-Based Drug Delivery
- Renal and Vascular Pathologies
- Blood Pressure and Hypertension Studies
- CAR-T cell therapy research
- Radiopharmaceutical Chemistry and Applications
Regeneron (United States)
2020-2023
Most antibody-drug conjugates (ADC) approved for the treatment of cancer contain protease-cleavable linkers. ADCs that traffic to lysosomes traverse highly acidic late endosomes, while recycle plasma membrane through mildly sorting and recycling endosomes. Although endosomes have been proposed process cleavable ADCs, precise identity relevant compartments their relative contributions ADC processing remain undefined. Here we show a METxMET biparatopic antibody internalizes into rapidly...
<p>Cathepsins</p>
<p>Dynasore</p>
<p>In vivo processing</p>
<p>Rabs KO Endocytosis</p>
<p>Recycling rounds</p>
<p>Endosomal itinerary</p>
<p>Recycling rounds</p>
<p>Endosomal itinerary</p>
<p>In vivo processing</p>
<p>Dynasore</p>
<p>Rabs KO Endocytosis</p>
<p>Cathepsins</p>
<div>Abstract<p>Most antibody–drug conjugates (ADC) approved for the treatment of cancer contain protease-cleavable linkers. ADCs that traffic to lysosomes traverse highly acidic late endosomes, while recycle plasma membrane through mildly sorting and recycling endosomes. Although endosomes have been proposed process cleavable ADCs, precise identity relevant compartments their relative contributions ADC processing remain undefined. Here we show a METxMET biparatopic antibody...
<div>Abstract<p>Most antibody–drug conjugates (ADC) approved for the treatment of cancer contain protease-cleavable linkers. ADCs that traffic to lysosomes traverse highly acidic late endosomes, while recycle plasma membrane through mildly sorting and recycling endosomes. Although endosomes have been proposed process cleavable ADCs, precise identity relevant compartments their relative contributions ADC processing remain undefined. Here we show a METxMET biparatopic antibody...
Abstract A biparatopic HER2xHER2 antibody drug conjugate with potent anti-tumor activity. The (ADC) Trastuzumab-emtansine (T-DM1) targets the well-characterized breast cancer oncogene HER2 and is active in tumors that express very high levels of protein. However, expressing intermediate remain resistant to T-DM1 therapy, apparently due insufficient lysosomal trafficking T-DM1. We generated a series antibodies which each arm recognizes distinct epitope HER2. One our bound cells greater...